Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 3/20 | 0.38 |
| ▸ | ITK | Q08881 | 5/20 | 0.34 |
| ▸ | INSR | P06213 | 3/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.33 |
| ▸ | IL6 | P05231 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4688017 | 0.93 | GRM1 (0.39) | GRM1ITKINSRCNR2NAMPT | |
| SCHEMBL4690792 | 0.93 | GRM1 (0.44) | GRM1ITKINSRTLR7IL6 | |
| SCHEMBL4688067 | 0.87 | GRM1 (0.38) | GRM1ITKINSRCNR2METTL3 | |
| Hydrochloric Acid SCHEMBL4688013 | 0.87 | GRM1 (0.46) | GRM1ITKINSRNAMPTMETTL3 | |
| Hydrochloric Acid SCHEMBL4691356 | 0.86 | GRM1 (0.39) | GRM1ITKINSRCNR2NAMPT | |
| SCHEMBL4694711 | 0.85 | GRM1 (0.42) | GRM1ITKCNR2NAMPT | |
| Hydrochloric Acid SCHEMBL4693204 | 0.84 | GRM1 (0.38) | GRM1ITKCNR2METTL3 | |
| Hydrochloric Acid SCHEMBL4691998 | 0.81 | METTL3 (0.39) | GRM1METTL3 | |
| SCHEMBL4688059 | 0.80 | GRM1 (0.45) | GRM1ITKINSRMETTL3 | |
| Hydrochloric Acid SCHEMBL4692131 | 0.80 | GRM1 (0.40) | GRM1ITKINSRCNR2METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1486501-B1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-7250429-B2 | Aminomethyl-substituted thiazolobenzimidazole compounds | ASTELLAS PHARMA INC. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1486501-A1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | GRM1, GRIN1, GRM3 | GRM1 1/4885ITK 3595/4885INSR 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.